# POT1

## Overview
The POT1 gene encodes the protein protection of telomeres 1, which is a critical component of the shelterin complex involved in telomere maintenance and protection. As a single-stranded DNA-binding protein, POT1 plays a pivotal role in safeguarding telomeres from degradation and preventing them from being recognized as DNA breaks. This function is essential for maintaining chromosomal stability and regulating telomerase activity, the enzyme responsible for telomere elongation (Wu2006Pot1; Baumann2002Human). The protein's interaction with TPP1, another shelterin component, enhances its binding affinity to telomeric DNA and modulates telomerase activity, thereby contributing to telomere length regulation (Baumann2010Pot1). Mutations in the POT1 gene have been linked to various cancers and hereditary conditions, underscoring its clinical significance in genomic stability and cancer predisposition (Nathan2020A; Wu2020Role).

## Structure
The POT1 protein is a crucial component of the shelterin complex, which protects telomeres and regulates telomerase activity. Structurally, POT1 contains three oligonucleotide/oligosaccharide-binding (OB) folds and a Holliday Junction Resolvase (HJR) domain. The N-terminal region of POT1 includes two OB folds (OB1 and OB2) that specifically bind to telomeric single-stranded DNA (ssDNA), recognizing the sequence 5'-TTAGGGTTAG-3'. OB1 binds the first six nucleotides, while OB2 binds the last four nucleotides (Smith2022Insights).

The C-terminal region of POT1 comprises the third OB fold (OB3) and the HJR domain, which are involved in interactions with TPP1, another component of the shelterin complex. This interaction is essential for telomere protection and telomerase regulation (Chen2017Structural; Smith2022Insights). The POT1-TPP1 complex adopts an elongated V-shaped conformation, which is suited for binding to the 3' end of the telomeric overhang and internal single-stranded telomeric regions (Chen2017Structural).

Mutations in the C-terminal OB3 domain of POT1 can disrupt its interaction with TPP1, leading to telomere instability and are associated with cancer (Chen2017Structural). The structural flexibility of POT1, particularly in its OB folds, may enhance its binding efficiency to telomeric repeats, aiding in telomere protection (Smith2022Insights).

## Function
The human POT1 (protection of telomeres 1) gene encodes a protein that plays a critical role in telomere maintenance and protection. POT1 binds specifically to the single-stranded G-rich overhang of telomeric DNA, preventing telomeres from being recognized as DNA breaks and protecting them from degradation (Wu2006Pot1; Baumann2002Human). This binding is essential for maintaining chromosomal stability and preventing inappropriate DNA repair activities (Baumann2010Pot1).

POT1 is a component of the shelterin complex, which includes other telomeric proteins such as TRF1 and TRF2. Within this complex, POT1 regulates telomere length by inhibiting telomerase, the enzyme responsible for telomere elongation. It achieves this by sequestering the telomeric DNA terminus, making it inaccessible to telomerase (Ye2004POT1interacting; Baumann2010Pot1). POT1 also interacts with TPP1, enhancing its binding affinity to telomeric DNA and further regulating telomerase activity (Baumann2010Pot1).

In healthy human cells, POT1 is crucial for preventing telomere dysfunction and genomic instability. Its depletion can lead to telomere elongation and a DNA damage response, highlighting its role in telomere protection and cellular senescence (Wu2006Pot1; Hockemeyer2005POT1).

## Clinical Significance
Mutations in the POT1 gene are associated with a wide range of cancers and hereditary conditions. Germline mutations in POT1 have been identified in familial cases of cutaneous melanoma, chronic lymphocytic leukemia (CLL), angiosarcoma, and glioma, indicating a predisposition to these cancers (Nathan2020A; Wu2020Role). Specific variants, such as the p.D224N, have been linked to multiple cancers, including melanoma, follicular lymphoma, and colorectal cancer, by disrupting POT1's ability to bind telomeric DNA, leading to telomere elongation and fragility (Nathan2020A).

Loss-of-function variants in POT1 are implicated in a tumor predisposition syndrome (POT1-TPDS), which includes uveal melanoma, colorectal cancer, and thyroid cancer (Nathan2020Lossoffunction). These mutations often result in longer telomeres and genomic instability, contributing to cancer development (Gu2016Pot1).

Alterations in POT1 expression levels are also significant. Overexpression is observed in early-stage CLL and other cancers, while downregulation is noted in breast cancer, potentially contributing to oncogenesis (Wu2020Role). The clinical significance of POT1 mutations lies in their potential to increase cancer susceptibility through telomere dysfunction and genomic instability (Wu2020Role).

## Interactions
POT1 (protection of telomeres 1) is a crucial component of the shelterin complex, interacting with both proteins and nucleic acids to maintain telomere integrity. It binds specifically to single-stranded telomeric DNA, recognizing the telomeric nonamer 5'-TAGGGTTAG-3' and optimally binding to [TTAGGG]n sequences (Loayza2004DNA). This interaction is essential for protecting chromosome ends and regulating telomerase activity.

POT1 forms a stable heterodimer with TPP1, another shelterin component, which is critical for its localization to telomeres and for enhancing its DNA binding affinity by 10-fold (Rice2017Structural). The POT1-TPP1 complex adopts an elongated V-shaped conformation, facilitating its role in telomere protection and telomerase recruitment (Chen2017Structural). The interaction between POT1 and TPP1 involves the C-terminal domain of POT1 and the POT1-binding module of TPP1, with specific residues contributing to this binding (Chen2017Structural).

Mutations in POT1 can disrupt its interaction with TPP1, leading to telomere instability and increased susceptibility to cancer (Chen2017Structural). These mutations often affect the OB folds of POT1, which are crucial for its DNA binding and interaction with TPP1 (Rice2017Structural).


## References


[1. (Smith2022Insights) Emmanuel W. Smith, Simon Lattmann, Zhehui Barry Liu, Bilal Ahsan, and Daniela Rhodes. Insights into pot1 structural dynamics revealed by cryo-em. PLOS ONE, 17(2):e0264073, February 2022. URL: http://dx.doi.org/10.1371/journal.pone.0264073, doi:10.1371/journal.pone.0264073. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0264073)

[2. (Wu2020Role) Yangxiu Wu, Rebecca C. Poulos, and Roger R. Reddel. Role of pot1 in human cancer. Cancers, 12(10):2739, September 2020. URL: http://dx.doi.org/10.3390/cancers12102739, doi:10.3390/cancers12102739. This article has 42 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers12102739)

[3. (Gu2016Pot1) P Gu, Y Wang, K K Bisht, L Wu, L Kukova, E M Smith, Y Xiao, S M Bailey, M Lei, J Nandakumar, and S Chang. Pot1 ob-fold mutations unleash telomere instability to initiate tumorigenesis. Oncogene, 36(14):1939–1951, November 2016. URL: http://dx.doi.org/10.1038/onc.2016.405, doi:10.1038/onc.2016.405. This article has 50 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/onc.2016.405)

[4. (Wu2006Pot1) Ling Wu, Asha S. Multani, Hua He, Wilfredo Cosme-Blanco, Yu Deng, Jian Min Deng, Olga Bachilo, Sen Pathak, Hidetoshi Tahara, Susan M. Bailey, Yibin Deng, Richard R. Behringer, and Sandy Chang. Pot1 deficiency initiates dna damage checkpoint activation and aberrant homologous recombination at telomeres. Cell, 126(1):49–62, July 2006. URL: http://dx.doi.org/10.1016/j.cell.2006.05.037, doi:10.1016/j.cell.2006.05.037. This article has 318 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.cell.2006.05.037)

[5. (Chen2017Structural) Cong Chen, Peili Gu, Jian Wu, Xianyun Chen, Shuangshuang Niu, Hong Sun, Lijie Wu, Na Li, Junhui Peng, Shaohua Shi, Cuiying Fan, Min Huang, Catherine C. L. Wong, Qingguo Gong, Chandan Kumar-Sinha, Rongguang Zhang, Lajos Pusztai, Rekha Rai, Sandy Chang, and Ming Lei. Structural insights into pot1-tpp1 interaction and pot1 c-terminal mutations in human cancer. Nature Communications, April 2017. URL: http://dx.doi.org/10.1038/ncomms14929, doi:10.1038/ncomms14929. This article has 70 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ncomms14929)

[6. (Loayza2004DNA) Diego Loayza, Heather Parsons, Jill Donigian, Kristina Hoke, and Titia de Lange. Dna binding features of human pot1. Journal of Biological Chemistry, 279(13):13241–13248, March 2004. URL: http://dx.doi.org/10.1074/jbc.m312309200, doi:10.1074/jbc.m312309200. This article has 130 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m312309200)

[7. (Rice2017Structural) Cory Rice, Prashanth Krishna Shastrula, Andrew V. Kossenkov, Robert Hills, Duncan M. Baird, Louise C. Showe, Tzanko Doukov, Susan Janicki, and Emmanuel Skordalakes. Structural and functional analysis of the human pot1-tpp1 telomeric complex. Nature Communications, April 2017. URL: http://dx.doi.org/10.1038/ncomms14928, doi:10.1038/ncomms14928. This article has 89 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ncomms14928)

[8. (Baumann2010Pot1) Peter Baumann and Carolyn Price. Pot1 and telomere maintenance. FEBS Letters, 584(17):3779–3784, May 2010. URL: http://dx.doi.org/10.1016/j.febslet.2010.05.024, doi:10.1016/j.febslet.2010.05.024. This article has 56 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.febslet.2010.05.024)

[9. (Baumann2002Human) Peter Baumann, Elaine Podell, and Thomas R. Cech. Human pot1 (protection of telomeres) protein: cytolocalization, gene structure, and alternative splicing. Molecular and Cellular Biology, 22(22):8079–8087, November 2002. URL: http://dx.doi.org/10.1128/MCB.22.22.8079-8087.2002, doi:10.1128/mcb.22.22.8079-8087.2002. This article has 243 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/MCB.22.22.8079-8087.2002)

[10. (Ye2004POT1interacting) Jeffrey Zheng-Sheng Ye, Dirk Hockemeyer, Andrew N. Krutchinsky, Diego Loayza, Sarah M. Hooper, Brian T. Chait, and Titia de Lange. Pot1-interacting protein pip1: a telomere length regulator that recruits pot1 to the tin2/trf1 complex. Genes &amp; Development, 18(14):1649–1654, July 2004. URL: http://dx.doi.org/10.1101/gad.1215404, doi:10.1101/gad.1215404. This article has 354 citations.](https://doi.org/10.1101/gad.1215404)

[11. (Nathan2020A) Vaishnavi Nathan, Peter A. Johansson, Jane M. Palmer, Hayley R. Hamilton, Madeleine Howlie, Kelly M. Brooks, Nicholas K. Hayward, and Antonia L. Pritchard. A rare missense variant in protection of telomeres 1 (pot1) predisposes to a range of haematological malignancies. British Journal of Haematology, November 2020. URL: http://dx.doi.org/10.1111/bjh.17218, doi:10.1111/bjh.17218. This article has 4 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/bjh.17218)

[12. (Hockemeyer2005POT1) Dirk Hockemeyer, Agnel J Sfeir, Jerry W Shay, Woodring E Wright, and Titia de Lange. Pot1 protects telomeres from a transient dna damage response and determines how human chromosomes end. The EMBO Journal, 24(14):2667–2678, June 2005. URL: http://dx.doi.org/10.1038/sj.emboj.7600733, doi:10.1038/sj.emboj.7600733. This article has 234 citations.](https://doi.org/10.1038/sj.emboj.7600733)

[13. (Nathan2020Lossoffunction) Vaishnavi Nathan, Jane M Palmer, Peter A Johansson, Hayley R Hamilton, Sunil K Warrier, William Glasson, Lindsay A McGrath, Vivian F S Kahl, Raja S Vasireddy, Hilda A Pickett, Kelly M Brooks, Antonia L Pritchard, and Nicholas K Hayward. Loss-of-function variants in pot1 predispose to uveal melanoma. Journal of Medical Genetics, 58(4):234–236, September 2020. URL: http://dx.doi.org/10.1136/jmedgenet-2020-107098, doi:10.1136/jmedgenet-2020-107098. This article has 5 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1136/jmedgenet-2020-107098)